Safety and efficacy of Ofatumumab in chronic lymphocytic leukemia: a systematic review and meta-analysis

References

• Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005 Feb 24;352(8):804–815. doi: 10.1056/NEJMra041720
   PubMed Web of Science ®Google Scholar
• D'Arena G, Di Renzo N, Brugiatelli M, et al. Biological and clinical heterogeneity of B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2003 Feb;44(2):223–228. doi: 10.1080/1042819021000035756
   PubMed Web of Science ®Google Scholar
• Redaelli A, Laskin BL, Stephens JM, et al. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care (Engl). 2004 Jul;13(3):279–287. doi: 10.1111/j.1365-2354.2004.00489.x
   PubMed Web of Science ®Google Scholar
• Dores GM, Anderson WF, Curtis RE, et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol. 2007 Dec;139(5):809–819. doi: 10.1111/j.1365-2141.2007.06856.x
   PubMed Web of Science ®Google Scholar
• Elphee EE. Caring for patients with chronic lymphocytic leukemia. Clin J Oncol Nurs. 2008 Jun;12(3):417–423. doi: 10.1188/08.CJON.417-423
   PubMed Web of Science ®Google Scholar
• Evans J, Ziebland S, Pettitt AR. Incurable, invisible and inconclusive: watchful waiting for chronic lymphocytic leukaemia and implications for doctor-patient communication. Eur J Cancer Care (Engl). 2012 Jan;21(1):67–77. doi: 10.1111/j.1365-2354.2011.01278.x
   PubMed Web of Science ®Google Scholar
• Messori A, Fadda V, Maratea D, et al. First-line treatments for chronic lymphocytic leukaemia: interpreting efficacy data by network meta-analysis. Ann Hematol. 2015 Jun;94(6):1003–1009. doi: 10.1007/s00277-015-2310-6
   PubMed Web of Science ®Google Scholar
• Bauer K, Rancea M, Roloff V, et al. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database Syst Rev. 2012 Nov 14;11:CD008079.
   PubMedGoogle Scholar
• Lemery SJ, Zhang J, Rothmann MD, et al. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res. 2010 Sep 01;16(17):4331–4338. doi: 10.1158/1078-0432.CCR-10-0570
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010 Apr 01;28(10):1749–1755. doi: 10.1200/JCO.2009.25.3187
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015 Nov;45(Pt A):139–145. doi: 10.1016/j.cct.2015.09.002
   PubMed Web of Science ®Google Scholar
• Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959 Apr;22(4):719–748.
   PubMed Web of Science ®Google Scholar
• Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997 Sep 13;315(7109):629–634. doi: 10.1136/bmj.315.7109.629
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 Jul 17;371(3):213–223. doi: 10.1056/NEJMoa1400376
   PubMed Web of Science ®Google Scholar
• Österborg A, Udvardy M, Zaritskey A, et al. Phase III, randomized study of ofatumumab versus physicians’ choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2016 Sep;57(9):2037–2046. doi: 10.3109/10428194.2015.1122783
   PubMed Web of Science ®Google Scholar
• van Oers MH, Kuliczkowski K, Smolej L, et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2015 Oct;16(13):1370–1379. doi: 10.1016/S1470-2045(15)00143-6
   PubMed Web of Science ®Google Scholar
• Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015 May 09;385(9980):1873–1883. doi: 10.1016/S0140-6736(15)60027-7
   PubMed Web of Science ®Google Scholar
• Robak T, Warzocha K, Govind Babu K, et al. Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leuk Lymphoma. 2016 Oct;12:1–10.
   Google Scholar
• Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1–2 study. Blood. 25 Oct 2007;111(3):1094–1100. doi: 10.1182/blood-2007-09-111781
   PubMed Web of Science ®Google Scholar
• Wierda WG, Padmanabhan S, Chan GW, et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood. 2011 Nov 10;118(19):5126–5129. doi: 10.1182/blood-2011-04-348656
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Ogura M, Suzuki T, et al. A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Int J Hematol. 2013 Aug;98(2):164–170. doi: 10.1007/s12185-013-1393-x
   PubMed Web of Science ®Google Scholar
• Ogura M, Hatake K, Tobinai K, et al. Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Jpn J Clin Oncol. 2013 May;43(5):466–475. doi: 10.1093/jjco/hyt022
   PubMed Web of Science ®Google Scholar
• Österborg A, Wierda WG, Mayer J, et al. Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients. Br J Haematol. 2015 Jul;170(1):40–49. doi: 10.1111/bjh.13380
   PubMed Web of Science ®Google Scholar
• Patton WN, Lindeman R, Butler AC, et al. An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2015;56(10):2819–2825. doi: 10.3109/10428194.2015.1014357
   PubMed Web of Science ®Google Scholar
• Moreno C, Montillo M, Panayiotidis P, et al. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European research initiative on chronic lymphocytic leukemia. Haematologica. 2015 Apr;100(4):511–516. doi: 10.3324/haematol.2014.118158
   PubMed Web of Science ®Google Scholar
• Flinn IW, Ruppert AS, Harwin W, et al. A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia. Am J Hematol. 2016 Oct;91(10):1020–1025. doi: 10.1002/ajh.24468
   PubMed Web of Science ®Google Scholar
• Rupp T, Zuckerman D. Quality of life, overall survival, and costs of cancer drugs approved based on surrogate endpoints. JAMA Intern Med. 2017 Feb;177(2):276–277.
   PubMed Web of Science ®Google Scholar
• Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: An analysis of 5 years of US food and drug administration approvals. JAMA Intern Med. 2015 Dec;175(12):1992–1994. doi: 10.1001/jamainternmed.2015.5868
   PubMed Web of Science ®Google Scholar
• Korycka-Wołowiec A, Wołowiec D, Robak T. Ofatumumab for treating chronic lymphocytic leukemia: a safety profile. Expert Opin Drug Saf. 2015;14(12):1945–1959. doi: 10.1517/14740338.2015.1113253
   PubMed Web of Science ®Google Scholar